| Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma (NCT05700448) | CStone Pharmaceuticals | 2027-06-01 |
| A Phase I Study of CS5007 in Participants With Advanced Solid Tumors (NCT07622524) | CStone Pharmaceuticals | 2026-07-16 |
| A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors (NCT06741644) | CStone Pharmaceuticals | 2025-02-24 |
| Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World (NCT05381753) | CStone Pharmaceuticals | 2022-08-29 |
| A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer (NCT05297890) | CStone Pharmaceuticals | 2022-05-27 |
| Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients (NCT04421352) | CStone Pharmaceuticals | 2021-01-12 |
| A Study of CS3005 in Advanced Solid Tumors (NCT04233060) | CStone Pharmaceuticals | 2020-01-10 |
| A Study of CS3002 in Subjects With Advanced Solid Tumors (NCT04162301) | CStone Pharmaceuticals | 2019-12-30 |
| A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors (NCT04338724) | CStone Pharmaceuticals | 2019-12-27 |
| A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma (NCT04187352) | CStone Pharmaceuticals | 2019-12-19 |
| A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma (NCT04194801) | CStone Pharmaceuticals | 2019-12-16 |
| A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors (NCT04200404) | CStone Pharmaceuticals | 2019-12-13 |
| A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma (NCT04194775) | CStone Pharmaceuticals | 2019-12-13 |
| A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation (NCT04176393) | CStone Pharmaceuticals | 2019-11-12 |
| A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor (NCT04254939) | CStone Pharmaceuticals | 2019-08-15 |
| A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma (NCT03802591) | CStone Pharmaceuticals | 2019-03-28 |
| A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer (NCT03789604) | CStone Pharmaceuticals | 2018-12-13 |
| A Study of CS1001 in Subjects with Advanced Solid Tumors (NCT03744403) | CStone Pharmaceuticals | 2018-12-04 |
| A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas (NCT03809767) | CStone Pharmaceuticals | 2018-10-29 |
| A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer (NCT03728556) | CStone Pharmaceuticals | 2018-10-26 |
| Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors (NCT03736850) | CStone Pharmaceuticals | 2018-10-19 |
| A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors (NCT03516123) | CStone Pharmaceuticals | 2018-06-14 |
| A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL) (NCT03595657) | CStone Pharmaceuticals | 2018-06-12 |
| A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT03505996) | CStone Pharmaceuticals | 2018-05-22 |
| A Study of CS1003 in Subjects With Advanced Solid Tumors (NCT03475251) | CStone Pharmaceuticals | 2018-05-09 |
| A Study of CS1002 in Subjects with Advanced Solid Tumors (NCT03523819) | CStone Pharmaceuticals | 2018-04-26 |
| A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors (NCT03312842) | CStone Pharmaceuticals | 2017-10-19 |